Julie Feder
Director of Finance/CFO presso AURA BIOSCIENCES, INC.
Patrimonio netto: 1 M $ in data 31/03/2024
Profilo
Julie B.
Feder is the Chief Financial Officer at Aura Biosciences, Inc. She previously held the same position at Verastem, Inc. and Clinton Health Access Initiative.
Prior to that, she worked as a Senior Manager at Deloitte & Touche LLP and as Vice President-Internal Audit at Genzyme Corp.
Feder received her undergraduate degree from Sy Syms School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0.27% | 01/02/2024 | 134 276 ( 0.27% ) | 1 M $ | 31/03/2024 |
Posizioni attive di Julie Feder
| Società | Posizione | Inizio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Director of Finance/CFO | 01/08/2018 |
Precedenti posizioni note di Julie Feder
| Società | Posizione | Fine |
|---|---|---|
| VERASTEM, INC. | Director of Finance/CFO | 01/06/2018 |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Director of Finance/CFO | 01/07/2017 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2008 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | - |
Formazione di Julie Feder
| Sy Syms School of Business | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Commercial Services |
- Borsa valori
- Insiders
- Julie Feder
